US FDA Convinced: Cosmetic Adverse Event Reports Aren’t Telling Whole Story
Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.
You may also be interested in...
The International Cooperation on Cosmetics Regulations continues efforts to minimize barriers to international trade through regulatory convergence, while also taking steps to educate consumers on cosmetics safety issues that may be widely misunderstood. Personal Care Products Council leadership discusses developments from the regulator group’s 15th annual meeting in June.
Beautycounter and Burt’s Bees are among the most vocal companies pushing for modernization of US cosmetics regulations via the proposed Personal Care Products Safety Act, which would require the FDA to establish a “natural” definition for use in product labeling.
In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.